Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Myelodysplastic Syndromes 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Myeloid, Acute 9Leukemia 9Hematologic Neoplasms 7Lymphoma, Non-Hodgkin 6Lymphoma 5Primary Immunodeficiency Diseases 3Multiple Myeloma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Cytopenia 3Anemia, Aplastic 3Thalassemia 2Osteopetrosis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoproliferative Disorders 2Immune System Diseases 2Hodgkin Disease 2Hemoglobinopathies 2Fanconi Anemia 2Anemia, Sickle Cell 2Anemia, Diamond-Blackfan 2Anemia 2Uveal Melanoma 1Recurrence 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoproliferative Disorders 1

Interventions

siltuximab 1fludarabine phosphate 1fludarabine 1Metoprolol 1Infliximab 1Etanercept 1Cyclophosphamide 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × AP 1903 reagent × Other hematologic neoplasm × Clear all
NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡